tm
Seeing Is Believing
tm
Seeing Is Believing
Currently, out of the existing stock ratings of Jonathan Chang - 70 which are a Buy (66.04%), 36 which are a Hold (33.96%)
Analyst Jonathan Chang works at LEERINK and is covering the Healthcare sector with 178 price targets and ratings displayed on 19 stocks.
Jonathan Chang's average stock forecast success ratio is 44.3% with an average time for price targets to be met of 143.37 days.
Most recent stock forecast was given on KPTI, Karyopharm Therapeutics at 10-Jan-2023.
Analyst best performing recommendations are on IMGN (IMMUNOGEN).
The best stock recommendation documented was for IMGN (IMMUNOGEN) at 11/30/2021. The price target of $7 was fulfilled within 2 days with a profit of $0.83 (13.45%) receiving and performance score of 67.26.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Sell
1
$0.55 (122.22%)
4
3 months 20 days ago
1/3 (33.33%)
$1.32 (12.68%)
21
Buy
10 months 27 days ago
0/1 (0%)
$7.45 (98.68%)
Buy
9
$8.22 (1053.85%)
9
1 years 21 days ago
2/3 (66.67%)
$1.29 (98.13%)
340
Hold
3
1 years 7 months 25 days ago
1/3 (33.33%)
$1.18 (39.59%)
377
Buy
6
$5.22 (669.23%)
16
4 years 6 months 23 days ago
1/3 (33.33%)
$6.36 (92.59%)
388
What Year was the first public recommendation made by Jonathan Chang?
